Navigation Links
MedQuist Announces Completion of Spheris Transaction
Date:4/23/2010

MT. LAUREL, N.J., April 23 /PRNewswire-FirstCall/ -- MedQuist Inc. (Nasdaq: MEDQ), a leading provider of technology-enabled clinical documentation services, today announces that it has completed the purchase of the domestic business of Spheris Inc.  Simultaneously, CBay Inc., MedQuist's majority owner, has acquired the stock of Spheris India Private Limited, a subsidiary of Spheris.  Together, the combined companies will offer unprecedented opportunities for healthcare providers to improve their clinical documentation and drive toward EHR adoption faster and at a lower cost, through the advanced technology and domestic and global services now available.

MedQuist CEO Peter Masanotti comments, "This is a very exciting development for the clinical documentation industry and the healthcare facilities we serve.  We are pleased to welcome Spheris customers and employees to MedQuist.  We pursued this transaction knowing that Spheris' resources and experience would perfectly complement our suite of services and technologies to deliver cost-effective, high quality clinical documentation."

He adds, "Our recent results have demonstrated that the market has been very receptive to MedQuist technologies and services, and we expect that new synergies with Spheris will only help us to increase our momentum and enhance our offerings to current and prospective customers.  We look forward to leading the way in innovation and customer care as a strong, financially stable, fully integrated organization."

Both MedQuist and Spheris are coordinating customer communications and ongoing services to assure that historical high service levels and customer s
'/>"/>

SOURCE MedQuist Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MedQuist Reports First Quarter 2008 Results
2. MedQuist and StructuRad Form Partnership to Integrate Report Macros into SpeechQ for Radiology(TM)
3. MedQuist Announces Additions to Board of Directors
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... for the detection of foodborne pathogens, today announced that ... & Company Emerging Growth Conference on September 2 at ... New York Marriott Marquis. A live ... investor relations section of Roka Bioscience,s website at ...
(Date:8/26/2015)... Intrexon Corporation (NYSE: XON ), a ... its previously announced public offering of common stock, including ... option to purchase an additional 731,707 shares of common ... share.  The exercise of the underwriters, option brought the ... Intrexon to 5,609,756 shares and increased the total gross ...
(Date:8/26/2015)... 26, 2015 Despite recent ... the optimism in biotech,s forecast is the recent ... sciences advancements.  Active biotechnology & healthcare companies with ... (OTCQB: PBIO), Sequenom, Inc. (NASDAQ: SQNM ), ... Pharmaceutical Corp. (NASDAQ: RPTP ) and EnteroMedics ...
(Date:8/25/2015)... ... August 25, 2015 , ... ... tissue lesions are cancerous is described by University of Illinois researchers in the ... optics and photonics. , In “ Breast cancer diagnosis using spatial light interference ...
Breaking Biology Technology:Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4
... its Construction Unit, aims to increase the efficiency, reduce ... solutions for contaminated sites and for building development itself. ... and currently scientific work is being undertaken which shows ... for the recovery of contaminated soils. At present the ...
... Corporation (Nasdaq: DNDN ) today announced the ... the impact of labeled and unlabeled use of PROVENGE® ... prostate cancer. This panel was convened as a part ... by the Centers for Medicare and Medicaid Services (CMS). ...
... Session ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
Cached Biology Technology:Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence 2Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence 3Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 2Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 3Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 4Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 5Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 6Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 7Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 8Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 9Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 10
(Date:7/31/2015)... -- Die 10. internationale Konferenz zu Genomik (ICG-10, ... findet vom 22. bis 25. Oktober 2015 in ... Die Konferenz feiert in diesem Jahr ... die ICG weltweit zu einem der einflussreichsten jährlichen ... der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
(Date:7/31/2015)... 31, 2015 The 10 th International Conference ... BGI from October 22-25, 2015, in Shenzhen , ... is celebrating its 10 th anniversary this year. Since its ... most influential annual meetings in the ,omics, fields, and is ... ICG-10 focuses on recent breakthroughs and advances ...
(Date:7/27/2015)... July 27, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Huawei has selected the ... for its stylish smartwatch. Huawei chose the state-of-the-art ... low power and highly responsive human interface qualities ... designers also required a classic round watch face ...
Breaking Biology News(10 mins):Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... climate change causes changes in the species composition of ... also to fish populations. Previous studies demonstrating a link ... entirely on statistical data. However, in order to estimate ... understanding of the effect of water temperature on the ...
... Researchers have made a breakthrough by detecting the electrical ... takes them a step closer to both seeing the ... test drugs. , To stay alive, individual biological ... their cell membranes. This flow produces an electrical current ...
... a major risk factor for Alzheimer's disease puts out the welcome ... to be more active in the brain compared to other forms ... Neurobiology of Aging, add some scientific heft to the idea, long ... bringing about Alzheimer's disease. , The work links a form of ...
Cached Biology News:How fish species suffer as a result of warmer waters 2A new study of living cells could revolutionize the way we test drugs 2Cold sore virus might play role in Alzheimer's disease 2Cold sore virus might play role in Alzheimer's disease 3Cold sore virus might play role in Alzheimer's disease 4
...
...
... The Zero Blunt TOPO PCR ... easiest method for high-efficiency (>=95%) cloning ... proofreading thermostable polymerases. The kit includes ... II-TOPO vector for 5-minute bench-top ligations ...
Carp Vitellogenin ELISA System, 96 wells. ELISARange: 5.0-225 ng/ml.Sensitivity: 5.0 ng/ml.Sample volume: 100 ul.Suitable for use with Carp plasma samples.3-h protocol.Store at 2-8 C. Category: Drug ...
Biology Products: